Madrid

• Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA) Ended
  2023-503525-19-00 3 Metastatic cancer
• LSTA1 Phase 2a basket trial in advanced solid tumors Ended
  2023-503740-14-00 4 Head and neck cancer
• European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatm … Ended
  2023-504282-23-00 1 Faecal incontinence
• Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended
  2023-504963-17-00 9 Advanced ccRCC
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 9 Oncology, NSCLC and CRC
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with … Ended
  2023-506240-16-00 9 Acute Myeloid Leukemia (AML)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors. Ended
  2023-506661-65-00 3 Advanced Solid Tumors
• A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended
  2023-506963-32-00 7 Participants with Phenylketonuria
• A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers Ended
  2023-507674-41-00 1 Advanced high-grade serous ovarian cancer (OC)
• Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after d … Ended
  2023-508583-30-00 9 Advanced/Recurrent Endometrial Cancer Patients with Disease Progressio
• MK-1200 for Advanced Solid Tumors Ended
  2023-508684-68-00 9 Advanced solid tumor
• Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended
  2023-508700-38-00 4 Metastatic or locally advanced unresectable solid tumors progressing a
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in post-COVID-19 POTS Ended
  2023-508744-22-00 5 Post-COVID-19 Postural Orthostatic Tachycardia Syndrome
• A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria … Ended
  2023-508992-35-00 4 Plaque Psoriasis
• NXP800 in subjects with Ovarian Cancer Ended
  2023-509150-64-00 1 Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary
• Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: … Ended
  2023-509879-16-00 6 Acute pancreatitis
• A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants … Ended
  2023-510340-20-00 3 Systemic Lupus Erythematosus
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Aller … Ended
  2024-511032-27-00 3 Severe IgE-mediated food allergy
• DIONYSIUS Ended
  2024-511743-26-00 6 Symptomatic Ischemic Ulcer related to Diabetes
• A Phase 1 study to look at RP-6306 in combination with FOLFIRI as a treatment for Advanced Solid Tumours Ended
  2024-511927-32-00 1 Advanced solid tumours
• An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma Ended
  2024-511949-19-00 1 Metastatic Melanoma
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar

Showing 3,505–3,528 of 3,550 trials